Ignite Creation Date:
2024-05-06 @ 8:25 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02735850
Status:
WITHDRAWN
Last Update Posted:
2017-05-23
First Post:
2016-03-22
Brief Title:
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer ImmunoSABR
Sponsor:
Maastricht Radiation Oncology
Organization:
Maastricht Radiation Oncology
Organization Data
Organization:
Maastricht Radiation Oncology
Class:
OTHER
Study ID:
Oligometas L19-IL2
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Maastricht Radiation Oncology
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| The Netherlands Cancer Institute | OTHER |
| Maastricht University Medical Center | OTHER |
| Karolinska Institutet | OTHER |
| University of Oxford | OTHER |
| KU Leuven | OTHER |
| Copenhagen University Hospital at Herlev | OTHER |
| Catholic University of the Sacred Heart | OTHER |